Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short Interest

Apollomics Inc. (NASDAQ:APLM) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 2,700 shares, a decrease of 82.0% from the August 31st total of 15,000 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 52,100 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 52,100 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.5% of the company’s stock are short sold.

Apollomics Stock Performance

Shares of APLM opened at $18.43 on Friday. Apollomics has a 12 month low of $3.66 and a 12 month high of $35.98. The firm has a fifty day simple moving average of $8.91 and a 200 day simple moving average of $7.27.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.